The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global allergy immunotherapies market reached a value of US$ 2.56 Billion in 2021. Looking forward, IMARC Group expects the marketto reach US$ 4.63 Billion by 2027, exhibiting at a CAGR of 10.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a preventive medical treatment for allergic reactions to allergens including various foods, drugs, bee venom, grass pollens and house dust mites. It alters the immune system’s response by gradually increasing the doses of the allergen. Before the treatment begins, an allergist and patient analyze triggering factors for allergy symptoms, which may involve skin and blood tests to confirm the allergens. Allergy immunotherapy helps in reducing inflammation, offering long-term impact, increasing immunological tolerance, changing the course of the disease and improving the quality of the patient’s life.
In recent years, there has been a rise in the prevalence of allergies around the world on account of various environmental and lifestyle factors that influence the functioning of the immune system. With the growing awareness of allergy immunotherapies, elevating income levels and increasing healthcare expenditure, the demand for sophisticated and long-term treatment options is increasing, which in turn is stimulating the growth of the market. It is further supported by the rising clinical research and development budget owing to several initiatives undertaken by both governmental and non-governmental organizations around the world. Further, with the latest drug development technologies, pharmaceutical firms have created more efficient immunotherapies for treating an array of allergies successfully. This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global allergy immunotherapies market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on treatment type, allergy type and distribution channel.
Breakup by Treatment Type:
Breakup by Allergy Type:
Breakup by Distribution Channel
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck Group, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Treatment Type, Allergy Type, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck Group, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global allergy immunotherapies market was valued at US$ 2.56 Billion in 2021.
We expect the global allergy immunotherapies market to exhibit a CAGR of 10.2% during 2022-2027.
The rising prevalence of several allergies based on environmental and lifestyle-based factors, along with
the growing consumer awareness towards numerous health benefits of allergy immunotherapies, is
currently driving the global allergy immunotherapies market.
The sudden outbreak of the COVID-19 pandemic has led to the rising adoption of allergy
immunotherapies in extensive R&D activities for analyzing the reaction of novel COVID-19 vaccines,
thereby augmenting the market growth.
Based on the treatment type, the global allergy immunotherapies market can be bifurcated into
Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), where Subcutaneous
Immunotherapy (SCIT) holds the majority of the total market share.
Based on the allergy type, the global allergy immunotherapies market has been segregated into allergic
rhinitis, asthma, food allergy, venom allergy, and others. Currently, allergic rhinitis represents the largest market share.
Based on the distribution channel, the global allergy immunotherapies market can be divided into
hospital pharmacy, retail pharmacy, and online pharmacy. Among these, hospital pharmacy accounts for
the majority of the total market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin
America, and Middle East and Africa, where Europe currently dominates the global market.
Some of the major players in the global allergy immunotherapies market include ALK-Abello A/S, Allergy
Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck Group, Aimmune
Therapeutics, Circassia Pharmaceuticals, Anergis SA, Biomay AG, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at